SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02938091

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Hepatic Lipase Variant -514 C/T in a High Fat vs. Low Fat Diet for Cardio-metabolic Outcomes: A Crossover Randomized Dietary Intervention Trial

The investigators evaluated dietary modulation of LIPC rs1800588 (-514 C/T) for lipids and glucose using a randomized cross-over design comparing a high-fat Western diet and a low-fat traditional Hispanic diet in Caribbean Hispanics (n=42; 4 weeks/phase).

NCT02938091 Dyslipidemia Impaired Glucose Tolerance
MeSH:Dyslipidemias Glucose Intolerance
HPO:Abnormal circulating lipid concentration

2 Interventions

Name: High-fat diet

Description: Typical Western diet
Type: Other
Group Labels: 1

High-fat diet

Name: Low-fat diet

Description: Traditional Caribbean Hispanic diet
Type: Other
Group Labels: 1

Low-fat diet

Primary Outcomes

Measure: change in fasting high-density lipoprotein cholesterol

Time: From date of randomization until completion of each 4 week dietary intervention

Secondary Outcomes

Measure: change in fasting plasma triglycerides

Time: From date of randomization until completion of the 4 week dietary intervention

Measure: change in fasting plasma glucose

Time: From date of randomization until completion of the 4 week dietary intervention

Measure: oral glucose tolerance test

Time: 2 hours post-oral glucose load

Measure: post-prandial lipemia 4 hours

Time: 4 hours post-oral fat load

Measure: post-prandial lipemia 8 hours

Time: 8 hours post-oral fat load
Purpose: Prevention

Allocation: Randomized

Crossover Assignment

There is one SNP

SNPs

1 rs1800588

Dietary Modulation of Hepatic Lipase (LIPC) -514 C/T Variant Associations With Lipids and Glucose The investigators evaluated dietary modulation of LIPC rs1800588 (-514 C/T) for lipids and glucose using a randomized cross-over design comparing a high-fat Western diet and a low-fat traditional Hispanic diet in Caribbean Hispanics (n=42; 4 weeks/phase).

Individuals were screened for LIPC rs1800588 genotype prior to enrollment, and genotype-associated differences in response to diet were evaluated.


HPO Nodes

HPO:
HP:0003119: Abnormal circulating lipid concentration
Genes 290
DCAF17 APOA2 PEX5 LMNA POLR3A PNPLA2 PRF1 PHYH APOB PMM2 TNFSF15 TDP1 SMPD1 PEX1 CPT2 PEX6 PIGT LMNA BSCL2 SPINK1 CYP19A1 XRCC4 ABCC8 HSD3B7 ABCG8 ACADVL LDLR AGPAT2 ADCY3 TTPA CETP LIMK1 OCRL TBL2 PEX2 BSCL2 UCP2 GK SLC29A3 SLC37A4 NADK2 ZMPSTE24 MCFD2 LTC4S CETP PEX10 MYO5A TRNL1 PSMB8 LMNA GPIHBP1 LMNB2 DGAT1 SLC12A1 TFG SC5D PEX19 PEX10 LCAT ACAD9 ACAD8 AR LMNA PEX2 MEF2A CTRC PEX7 RAI1 PIK3R5 CEP19 EBP PYGL ACADL BSCL2 POU2AF1 LIPE CFH APOB CLIP2 ACADM PEX5 FHL1 AEBP1 CAVIN1 ANGPTL3 PSMB9 HMGCL DHCR24 FOS FECH TMEM199 GHR PLVAP CYP11A1 LMNA DHCR7 XRCC4 SMPD1 SGPL1 EBP CCT5 PIGH MC4R APOA5 IL12RB1 IRF5 CAV1 STX11 DHCR7 ACAD8 IL12A TRNK AGL POLD1 SLC25A20 PPP1R17 ALMS1 ABHD5 UBE3B LRP6 APOA5 PRSS1 ABCA1 DYRK1B CCDC115 NGLY1 SYNE1 RAI1 LIPA APOA1 ALB FLII PEX7 LDLRAP1 SYNE2 TNPO3 LEPR MSMO1 TMEM43 LCAT FBN1 LDLR GLA SAR1B OCRL ABCG8 KCNJ11 TRMU ABCA1 LEP CAV1 NPC2 HAVCR2 BSCL2 LMNA COG4 ABCD1 IQSEC2 SLC25A13 LMNA GHR LPL UBR1 PEX13 PHKG2 SAR1B PEX11B APTX SLC25A13 CIDEC TBCK ALMS1 XIAP PPARG KCNJ1 PNPLA2 NPHS1 DLD AGL AKT2 GTF2I PEX1 ABCA1 POLR3A NPC1 CTNS SLC37A4 LIPC LMNA SLC25A13 JAG1 ZMPSTE24 LIPA PSMB4 MTTP PHKA2 NUP107 SLC7A7 LIPE ACTN4 CFHR1 APOE ABCA1 PEX14 TRNE APOC3 ACADVL EMD LPL APOC2 NUP107 HMBS CAV1 LDLRAP1 RAI1 LMNA ELN LMAN1 PEX26 ALB PEX19 RAB27A CYP27A1 CFHR3 LMNA TANGO2 ACOX2 FLCN CAVIN1 EPHX2 PPARG CYP7A1 PLIN1 BAZ1B SLC52A1 DEAF1 PEX5 GYS2 SLC22A5 HADH CPT1A NSDHL G6PC PCSK9 ZMPSTE24 PPARG APOC3 HNF1A TRNE NSMCE2 GPD1 CAV3 PANK2 RFC2 HNF4A UNC13D SLC25A13 MMEL1 NPHS2 PEX12 PEX16 PHKA2 PHKG2 TDP1 RSPO1 LMNA PLA2G4A ACADM PCSK9 DCAF17 APOB STXBP2 CIDEC PLA2G7 LBR SPIB NADK2 TANGO2 CYP11A1 PLIN1 PNLIP LCAT CPT1A ABCG5 PEX3 GTF2IRD1 PEX12 AGPAT2 CYP27A1 SETX
Protein Mutations 5
A1298C A54T C677T E167K I148M
SNP 1
rs1800588